Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Scribe Therapeutics announced a second success milestone in its in vivo CRISPR collaboration with Eli Lilly (NYSE: LLY), advancing a target for neurological and neuromuscular diseases. The achievement further validates Scribe’s X-Editor (XE) platform and CRISPR by Design engineering approach.
Under the 2023 agreement, Scribe is eligible for more than $1.5 billion in potential milestone payments across programs plus low-double-digit royalties, and the companies previously reported an initial milestone and a 2025 ASGCT presentation.
Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will appear in a fireside chat at 3:10 p.m. ET.
A live audio webcast will be available via Lilly's investor site under Webcasts & Presentations, with a replay accessible on the same site for approximately 90 days.
USOPC and Lilly (NYSE:LLY) announced the multi-year Team USA Athlete Recovery Program partnership, covering support after Milano Cortina 2026 through LA28.
The program expands a 2024 pilot that supported 10 athletes (6 qualified for Paris 2024), and Lilly will fund access, storytelling, and program growth over the next three years.
Lilly (NYSE:LLY) reported positive topline results from the Phase 3 LIBRETTO-432 trial: adjuvant Retevmo (selpercatinib) met the primary endpoint with a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) in early-stage (II-IIIA) RET fusion-positive NSCLC.
Overall survival trended favorably but was immature at analysis; safety was generally consistent with prior selpercatinib trials. Detailed data will be presented at a medical congress and submitted for peer review.
Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to advance in vivo cell therapies, announced Feb. 9, 2026. The deal could deliver up to $2.4 billion in cash to Orna shareholders, including an upfront payment and milestone payments tied to clinical development.
Orna's lead program, ORN-252, is a clinical trial-ready CD19-targeting in vivo CAR-T for B cell-driven autoimmune diseases, built on circular RNA and novel LNP delivery that may enable more durable therapeutic expression.
Eli Lilly (NYSE: LLY) reported Q4 2025 revenue of $19.3B, up 43%, and reported EPS of $7.39 (non-GAAP EPS $7.54). Full-year 2026 guidance targets $80–$83B revenue and non-GAAP EPS of $33.50–$35.00. Key drivers were strong volume growth for Mounjaro and Zepbound, regulatory progress on tirzepatide and Jaypirca, Phase 3 clinical wins, and a U.S. agreement to expand access to obesity medicines.
R&D and SG&A rose on pipeline and launches; gross margin was 82.5% in Q4 2025. 2026 performance margin guidance is 46.0%–47.5%.
Eli Lilly (NYSE: LLY) will invest more than $3.5 billion to build a new injectable medicine and device manufacturing site in Fogelsville, Lehigh Valley, Pennsylvania, focused on next-generation weight-loss therapies including retatrutide. The facility is expected to create 850 permanent jobs, 2,000 construction roles, and begin operations in 2031.
The site is Lilly's newest U.S. facility announced since 2020 and part of over $50 billion in capital expansion commitments to expand domestic medicine production.
Eli Lilly (NYSE: LLY) will report its fourth-quarter 2025 financial results on February 4, 2026. A conference call with the investment community and media will be held the same day beginning at 10 a.m. Eastern. Investors, media and the public can access a live webcast via the company's investor website, and a replay will be posted after the call.
Eli Lilly (NYSE: LLY) announced that the U.S. FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) on January 20, 2026 for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior bevacizumab and mirvetuximab soravtansine, if eligible.
Sofetabart mipitecan is an FRα antibody-drug conjugate using proprietary linker technology and an exatecan payload. The designation was based on encouraging preliminary Phase 1a/b results showing responses across all FRα expression levels, activity in patients who progressed after mirvetuximab soravtansine, and a tolerability profile with low rates of interstitial lung disease, peripheral neuropathy, and alopecia. Lilly has initiated the global Phase 3 FRAmework-01 trial (NCT07213804).
Summary not available.